n.a. (MAXY)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Maxygen Reports Fourth Quarter And Year End 2010 Financial Results

Maxygen Reports Fourth Quarter And Year End 2010 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Maxygen Announces Tax Treatment Of 2010 Distributions

Maxygen Announces Tax Treatment Of 2010 Distributions

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its distributions of Codexis, Inc.

Maxygen Announces Initiation Of Phase I Clinical Trial Under Perseid’s Collaboration With Astellas For CTLA4-Ig Program

Maxygen Announces Initiation Of Phase I Clinical Trial Under Perseid’s Collaboration With Astellas For CTLA4-Ig Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic...

Brocade, HP, PacSun: After-Hours Trading

Brocade, HP, PacSun: After-Hours Trading

Shares of Brocade Communications fell in late trades after the company's revenue forecast for its current fiscal first quarter disappointed Wall Street.

Maxygen Announces Distributions Of Codexis Shares And Cash

Maxygen Announces Distributions Of Codexis Shares And Cash

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will distribute substantially all of the shares of the common stock of Codexis, Inc.

Maxygen Reports Third Quarter 2010 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Maxygen Announces Sale Of MolecularBreeding™ Directed Evolution Platform Technology To Codexis

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it has sold its MolecularBreeding™ platform technology to Codexis, Inc.

Maxygen Reports Second Quarter 2010 Financial Results

Maxygen, Inc. (Nasdaq:MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Maxygen Announces Expiration Of Cangene’s Option To License MAXY-G34 For Acute Radiation Syndrome

Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its option and licensing arrangement with Cangene Corporation (TSX: CNJ) has expired.

Perseid Achieves Second Preclinical Milestone Under Collaboration With Astellas For CTLA-4 Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that its majority-owned subsidiary, Perseid Therapeutics LLC, achieved a second preclinical...

Maxygen Announces $10 Million Stock Repurchase Program

Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced a stock repurchase program under which the company may purchase up to $10 million of its common...

Maxygen Reports First Quarter 2010 Financial Results

Maxygen, Inc. (Nasdaq: MAXY), a biopharmaceutical company focused on developing improved versions of protein drugs through both internal development and external collaborations and other arrangements, today announced...

Enzyme Developer Codexis Files For $100M IPO

Enzyme and catalyst developer Codexis files for initial public offering worth up to $100M

In a Holding Pattern

Sellers haven't taken control of the tape, at least yet, as they're likely waiting for market-moving news this week.

Wednesday's Winners & Losers: SanDisk

Shares gain 8.6% after an analyst suggested NAND memory chip pricing could stabilize.

Health Winners & Losers: Maxygen

Maxygen climbs on news of a deal with Bayer HealthCare.

Friday's Winners & Losers: UAL

United Airlines' operator's shares are up 8.2% after the company announces new charges for checked bags.

Health Winners & Losers: Maxygen

Maxygen slides on news Amgen was granted a patent that may affect Maxygen's MAXY-G34, a possible treatment for chemotherapy-induced neutropenia.

Tuesday's Health Winners & Losers

Osiris Therapeutics rises on study results.

Monday's Health Winners & Losers

Medivation falls in response to a new sell rating.

Friday's Health Winners & Losers

Maxygen slumps.

Roche Halts Maxygen Drug Trial

Shares of the biotech fall after Roche puts hepatitis treatment MAXY-alpha on clinical development hold.

Wednesday's Early Winners & Losers

Air T rises after receiving a $13.8 million order from the U.S. Air Force.

A Couple of Gems Shine in Lackluster Lockup Expirations Area

Maxygen and Tibco continue to hold up, and should come out of their expirations unscathed.